Sonoma Pharmaceuticals Inc SNOA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.11 up $0.04, 3.74% at close Nov 6
Last close · Previous close $1.07
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.22Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.11down $0.12, 9.76%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.07Nov 5
- Volume44.53KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume39.25KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.85 to $3.95; now $1.11
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
SNOA trailed the S&P 500 in all 7 periods.
| Period | SNOA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SNOA: down 9.8% S&P 500: down 5.6% | SNOA trailed the S&P 500 by 4.2 percentage points Trailed |
| 3M | SNOA: down 11.2% S&P 500: down 4.1% | SNOA trailed the S&P 500 by 7.1 percentage points Trailed |
| YTD | SNOA: down 69.5% S&P 500: up 8.7% | SNOA trailed the S&P 500 by 78.2 percentage points Trailed |
| 1Y | SNOA: down 69.6% S&P 500: up 10.9% | SNOA trailed the S&P 500 by 80.5 percentage points Trailed |
| Long term | ||
| 3Y | SNOA: down 67.6% S&P 500: up 75.0% −31.3% vs +20.5% a year | SNOA trailed the S&P 500 by 142.6 percentage points Trailed |
| 5Y | SNOA: down 99.1% S&P 500: up 67.8% −60.6% vs +10.9% a year | SNOA trailed the S&P 500 by 166.9 percentage points Trailed |
| 10Y | SNOA: down 99.9% S&P 500: up 313.1% −48.3% vs +15.2% a year | SNOA trailed the S&P 500 by 413.0 percentage points Trailed |
$10,000 invested in SNOA 10 years ago (Nov 4, 2016) would be worth about $14 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
SNOA trailed the S&P 500 in all 7 periods.
| Period | SNOA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SNOA: down 9.8% S&P 500: down 5.6% | SNOA trailed the S&P 500 by 4.2 percentage points Trailed |
| 3M | SNOA: down 11.2% S&P 500: down 4.3% | SNOA trailed the S&P 500 by 6.9 percentage points Trailed |
| YTD | SNOA: down 69.5% S&P 500: up 7.8% | SNOA trailed the S&P 500 by 77.3 percentage points Trailed |
| 1Y | SNOA: down 69.6% S&P 500: up 9.7% | SNOA trailed the S&P 500 by 79.3 percentage points Trailed |
| Long term | ||
| 3Y | SNOA: down 67.6% S&P 500: up 68.8% −31.3% vs +19.1% a year | SNOA trailed the S&P 500 by 136.4 percentage points Trailed |
| 5Y | SNOA: down 99.1% S&P 500: up 56.9% −60.6% vs +9.4% a year | SNOA trailed the S&P 500 by 156.0 percentage points Trailed |
| 10Y | SNOA: down 99.9% S&P 500: up 252.6% −48.3% vs +13.4% a year | SNOA trailed the S&P 500 by 352.5 percentage points Trailed |
$10,000 invested in SNOA 10 years ago (Nov 4, 2016) would be worth about $14 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$69,300.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Jan 25, 2007.
Stock splits
4
Latest: 1-for-20 on . Share counts adjust after each split.
All 4 splits
- 1-for-20
- 1-for-9
- 1-for-5
- 1-for-7
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY27, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $21.92Mup 47.0%
- Net income
- −$2.26M
- Diluted EPS
- −$1.22
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY25 (Sep 30, 2024) | $3.58M | −$610.00K | −$0.59 |
| Q3 FY25 (Dec 31, 2024) | $3.56M | −$928.00K | −$0.63 |
| Q4 FY25 (Mar 31, 2025) | $3.75M | −$776.00K | −$0.39 |
| Q1 FY26 (Jun 30, 2025) | $4.02M | −$1.24M | −$0.76 |
| Q2 FY26 (Sep 30, 2025) | $5.60M | −$534.00K | −$0.32 |
| Q3 FY26 (Dec 31, 2025) | $4.35M | −$819.00K | −$0.48 |
| Q4 FY26 (Mar 31, 2026) | $5.56M | −$581.00K | −$0.33 |
| Q1 FY27 (Jun 30, 2026) | $6.41M | −$330.00K | −$0.09 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Mar 31, 2022) | $12.63M | −$5.09M | Paused See the note under the price. |
| FY23 (Mar 31, 2023) | $13.27M | −$5.15M | Paused See the note under the price. |
| FY24 (Mar 31, 2024) | $12.74M | −$4.84M | Paused See the note under the price. |
| FY25 (Mar 31, 2025) | $14.29M | −$3.46M | −$2.79 |
| FY26 (Mar 31, 2026) | $19.53M | −$3.18M | −$1.89 |
Margins
- Gross 38.9%
- Operating −6.4%
- Net −10.3%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$2.66MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$2.57MLast 12 months
- Capital spending$88.00KLast 12 months
- −12.1%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $3.98MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $5.34MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$739.00KAs of Jun 30, 2026
- Net cash$4.60MAs of Jun 30, 2026
- 2.99As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.11As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −53.6%Last 12 months
Over the last 12 months, Sonoma Pharmaceuticals lost money: its net loss was 53.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −15.2%Last 12 months
Over the last 12 months, Sonoma Pharmaceuticals’s net loss was 15.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The company's products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Colorado, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
SNOA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
SNOA stock FAQ
What is SNOA stock’s price today?
Sonoma Pharmaceuticals (SNOA) traded at $1.11 at the close on , up $0.04 (3.74%) from the previous close of $1.07. Over the past 52 weeks it has traded between $0.85 and $3.95.
If you invested $1,000 in SNOA 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in SNOA on would be worth about $1 at the close on , a total return of −99.9%. The same $1,000 would be worth $9 if invested five years ago and $304 if invested one year ago. Past performance doesn’t predict future returns.
What is SNOA’s P/E ratio?
SNOA’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.22).
How much revenue does Sonoma Pharmaceuticals make?
Sonoma Pharmaceuticals reported $21.9 million of revenue over the four quarters to , up 47.0% from the twelve months before. In its latest quarter (Q1 FY27, ended ) revenue was $6.4 million, up 59.6% from a year earlier.
Is Sonoma Pharmaceuticals profitable?
Not over the four quarters to . Sonoma Pharmaceuticals reported a net loss of $2.3 million across those four quarters on $21.9 million of revenue.
What are SNOA’s earnings per share?
SNOA’s diluted earnings per share were −$1.22 over the four quarters to , compared with −$2.37 in the twelve months before. The latest quarter (Q1 FY27) brought −$0.09 per share, against −$0.76 a year earlier (how EPS works).
Does SNOA pay a dividend?
Sonoma Pharmaceuticals hasn’t paid a dividend in the last twelve months.
What is SNOA’s 52-week high and low?
Over the past 52 weeks SNOA has traded as low as $0.85 and as high as $3.95. At $1.11 at the close on , it is 71.9% below that high and 30.6% above the low.
What is SNOA’s all-time high?
SNOA’s highest closing price was $69,300.00 on , adjusted for stock splits. At $1.11 at the close on , it is 100.0% below that record.
Has SNOA stock ever split?
Yes, four times: 1-for-7 on ; 1-for-5 on ; 1-for-9 on ; 1-for-20 on .
How has SNOA stock performed?
Including dividends and measured to the close on , SNOA has returned −69.5% so far this year and −69.6% over the past year, and −99.1% over five years (−60.6% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Sonoma Pharmaceuticals in?
Sonoma Pharmaceuticals is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in Colorado, USA.
What exchange does SNOA trade on?
Sonoma Pharmaceuticals trades on the Nasdaq under the ticker symbol SNOA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.